CA2302808A1 - 50 proteines secretees d'origine humaine - Google Patents

50 proteines secretees d'origine humaine Download PDF

Info

Publication number
CA2302808A1
CA2302808A1 CA002302808A CA2302808A CA2302808A1 CA 2302808 A1 CA2302808 A1 CA 2302808A1 CA 002302808 A CA002302808 A CA 002302808A CA 2302808 A CA2302808 A CA 2302808A CA 2302808 A1 CA2302808 A1 CA 2302808A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
polynucleotide
atcc deposit
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002302808A
Other languages
English (en)
Other versions
CA2302808C (fr
Inventor
Paul A. Moore
Steven M. Ruben
David W. Lafleur
Yanggu Shi
Craig A. Rosen
Henrik S. Olsen
Reinhard Ebner
Laurie A. Brewer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2302808A1 publication Critical patent/CA2302808A1/fr
Application granted granted Critical
Publication of CA2302808C publication Critical patent/CA2302808C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

La présente invention se rapporte à de nouvelles protéines sécrétées d'origine humaine et à des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. L'invention se rapporte également à des vecteurs, à des cellules hôtes, à des anticorps et à des procédés de recombinaison permettant de produire des protéines sécrétées humaines. Elle se rapporte en outre à des procédés diagnostiques et thérapeutiques conçus pour diagnostiquer et traiter des troubles liés à ces nouvelles protéines sécrétées humaines.
CA2302808A 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine Expired - Fee Related CA2302808C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US5766397P 1997-09-05 1997-09-05
US5766997P 1997-09-05 1997-09-05
US5762697P 1997-09-05 1997-09-05
US60/057,663 1997-09-05
US60/057,626 1997-09-05
US60/057,669 1997-09-05
US5866797P 1997-09-12 1997-09-12
US5897397P 1997-09-12 1997-09-12
US5866697P 1997-09-12 1997-09-12
US5897497P 1997-09-12 1997-09-12
US60/058,974 1997-09-12
US60/058,973 1997-09-12
US60/058,666 1997-09-12
US60/058,667 1997-09-12
PCT/US1998/018360 WO1999011293A1 (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine

Publications (2)

Publication Number Publication Date
CA2302808A1 true CA2302808A1 (fr) 1999-03-11
CA2302808C CA2302808C (fr) 2010-05-18

Family

ID=27568129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2302808A Expired - Fee Related CA2302808C (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine

Country Status (5)

Country Link
EP (1) EP1019091A4 (fr)
JP (2) JP2001514024A (fr)
AU (1) AU9130498A (fr)
CA (1) CA2302808C (fr)
WO (1) WO1999011293A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002591A1 (en) 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
JP2002513037A (ja) * 1998-04-24 2002-05-08 ジェネンテック・インコーポレーテッド Ｆｉｚｚタンパク質
WO2000064920A1 (fr) * 1999-04-27 2000-11-02 The Trustees Of The University Of Pennsylvania Compositions, methodes et kits se rapportant a la resistine
CA2397838A1 (fr) 2000-01-19 2001-07-26 University Of Virginia Patent Foundation Proteines specifiques du sperme
US7135559B2 (en) * 2000-02-21 2006-11-14 Kureha Chemical Industry Co., Ltd. Proteins and novel genes encoding the same
EP1138768A3 (fr) * 2000-03-27 2002-08-07 Leadd B.V. Protéine AAP-5 liant l' apoptine
EP1138765A1 (fr) * 2000-03-27 2001-10-04 Leadd B.V. Protéines AAP-5 et AAP-6 associées à l'apoptine
ATE360068T1 (de) * 2000-11-06 2007-05-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
WO2002057420A2 (fr) * 2001-01-18 2002-07-25 Human Genome Sciences, Inc. 50 proteines secretees humaines
EP1399460A4 (fr) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H Genes associes au cancer du sein et utilisations correspondantes
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
US20060099143A1 (en) 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
CA2694454A1 (fr) * 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Analogues de la chimiokine
RU2728717C1 (ru) 2017-06-02 2020-07-30 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Средство для профилактики или лечения спиноцеребеллярной атаксии
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
JP7227914B2 (ja) * 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528703A (en) * 1998-03-25 2005-05-27 Genentech Inc Novel PRO337 polypeptides and nucleic acids encoding a neurotrimin polypeptide

Also Published As

Publication number Publication date
EP1019091A4 (fr) 2005-05-11
AU9130498A (en) 1999-03-22
JP2001514024A (ja) 2001-09-11
CA2302808C (fr) 2010-05-18
JP2009131263A (ja) 2009-06-18
WO1999011293A1 (fr) 1999-03-11
EP1019091A1 (fr) 2000-07-19

Similar Documents

Publication Publication Date Title
CA2364567A1 (fr) Sequences et polypeptides geniques associes au cancer des ovaires et du sein
JP2002518010A5 (fr)
JP2002521055A5 (fr)
CA2323776A1 (fr) Analogue de chaine gamma commune de recepteur de cytokine
JP2002502589A5 (fr)
CA2247285A1 (fr) Facteurs de necrose tumorale delta et epsilon chez l'homme
JP2002516103A5 (fr)
CA2225189A1 (fr) Gene et proteine du facteur viii du chien et methodes d'utilisation
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
CA2309783A1 (fr) Facteur de croissance des fibroblastes 19
CA2343655A1 (fr) Proteine de type recepteur d'interleukine 17
McCaffery et al. Determination and analysis of the primary structure of the nerve terminal specific phosphoprotein, synapsin I.
JP2002506625A5 (fr)
CA2321089A1 (fr) Homologue humain de la proteine ?fused ? de drosophile
CA2252372A1 (fr) Proteine associee a un escherichia coli pathogene
CA2329054A1 (fr) Nouveau polypeptide phosphatonine hormonale
CA2343979A1 (fr) Interleukine humaine b50, ses utilisations therapeutiques
EP1284298A3 (fr) Identification et utilisation des molécules impliquées dans la douleur
CA2186573A1 (fr) Inositol-phosphatase renfermant du sh2
JP2002517193A5 (fr)
CA2294472A1 (fr) Torsine, genes de torsine et leurs utilisations
WO2000000607B1 (fr) Acide nucleique codant pour une proteine de liaison du retinoblastome (rbp-7) et marqueurs polymorphes associes a cet acide nucleique
KR970704887A (ko) 혈청 파라옥소나제
EP1284297A3 (fr) Identification et utilisation des molécules impliquées dans la douleur
EP1279744A3 (fr) Identification et utilisation des molécules impliquées dans la douleur

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed